source
- Seaport’s IPO adventure, obesity pill battles, and Makary’s troublesThis week on "The Readout LOUD" podcast: Seaport Therapeutics’ successful IPO, obesity pill battles, and the FDA commissioner's White House troubles.STAT · 2mo ago↗ source
- Science is becoming less disruptive. Is an aging workforce to blame?Most researchers conduct their more disruptive work early in their careers, but as they age, they tend to abandon that groundbreaking energySTAT · 2mo ago↗ source
- Dr Olawaiye on the FDA Approval of Relacorilant Plus Nab-Paclitaxel in PROCAlexander B. Olawaiye, MD, discusses the clinical significance of the FDA approval of relacorilant plus nab-paclitaxel in PROC.onclive · 2mo ago↗ source